
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1054 | 1032 | 1080 | 1093 | 1686 | - |
Fund Return | 5.41% | 3.24% | 7.99% | 3.02% | 11.01% | - |
Place in category | 330 | 395 | 252 | 266 | 69 | - |
% in Category | 74 | 88 | 64 | 73 | 15 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Eurose Class I shares E | 2.37B | 3.76 | 5.12 | 2.70 | ||
DNCA Invest Eurose Class AD shares | 2.37B | 3.66 | 4.38 | 1.97 | ||
DNCA Invest Eurose Class A shares | 2.37B | 3.66 | 4.38 | 1.96 | ||
DNCA Invest Europe Growth Class B s | 773.81M | 6.12 | 0.59 | 5.88 | ||
DNCA Invest Europe Growth Class F s | 773.81M | 6.40 | 2.24 | 7.41 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Europe Growth Class A s | 773.81M | 6.19 | 0.99 | 6.28 | ||
DNCA Invest Europe Growth Class B s | 773.81M | 6.12 | 0.59 | 5.88 | ||
DNCA Invest Europe Growth Class F s | 773.81M | 6.40 | 2.24 | 7.41 | ||
DNCA Invest Europe Growth Class I s | 773.81M | 6.36 | 2.04 | 7.28 | ||
LU1330191385 | 739.23M | 7.77 | 10.43 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 8.17 | 432.0 | -5.45% | |
Flutter Entertainment | IE00BWT6H894 | 6.60 | 16,085.0 | -2.75% | |
Bonesupport | SE0009858152 | 6.04 | 309.40 | -2.21% | |
SAP | DE0007164600 | 5.20 | 231.200 | -3.24% | |
AstraZeneca | GB0009895292 | 4.98 | 10,808.0 | -5.13% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review